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Sir,
We enjoyed the recent articles on cancer-associated thrombosis
and wish to comment on the attempts to explain the beneficial
effects of heparin in cancer (Noble and Pasi, 2010; Kakkar and
Macbeth, 2010).
Cited evidence indicates that the survival benefit of heparin
in cancer is unexplained by venous thromboembolism (VTE)
prophylaxis alone; unlike warfarin, heparin improves survival
in cancer patients without VTE (Zielinski and Hejna, 2000;
Cunningham et al, 2009). Alternative explanations independent
of VTE prophylaxis include regulation of tissue factor and FVIIa
with the TF–VIIa complex (Boccaccio and Comoglio, 2005; Rickles
and Falanga, 2009), inhibition of cancer micrometastasis by
blocking platelet and cancer cell aggregation (Borsig et al, 2001),
and disruption of host wound-healing responses (including clotting
and fibrin deposition) proposed to facilitate construction of tumour
microenvironment (Dvorak, 1986). Although these explanations do
not require VTE prophylaxis, they still relate to heparin’s clotting-
related effects.
Heparin is a multifunctional, highly sulphated form of heparan
sulphate (HS), a member of the glycosaminoglycan family. Given
the vast interactome of HS and related heparins (Ori et al, 2008), it
is unsurprising that heparin’s benefit in cancer cannot be linked
solely to its anti-coagulant activity (Fuster and Esko, 2005; Escobar
Galvis et al, 2007). Estimated to carry far more information than
nucleic acids, the HS family are ubiquitous, varied and highly
complex regulators of normal organogenesis (e.g., through growth
factor modulation) with pleiotropic biological effects unrelated to
anti-coagulation (Bishop and Schuksz Esko, 2007). Likewise,
heparin has diverse, structure-related biological properties, only
one of which is anti-coagulation and this can be manipulated
through judicious structural modification to generate low-mole-
cular-weight derivatives with improved selectivity (Norrby, 1993).
Clinicians glimpsed heparin’s diversity during replacement of
unfractionated heparins with fractionated low-molecular-weight
alternatives (although the focus remained anti-coagulation).
If they are entirely anti-coagulant related, further exploitation of
heparin’s benefits in cancer is inevitably limited by haemorrhage
risk. However, by separating anti-coagulant from other bioactiv-
ities, ‘engineered’ (selectively modified) heparins provide the
means to test whether heparins mediate their benefits in cancer
independently of coagulation effects, as has been achieved for
other biological activities such as inhibition of b-secretase or blood
cell rosetting in malaria (Patey et al, 2006; Yates et al, 1996;
Skidmore et al, 2008). Such developments offer the prospect of
screening and developing a broad new class of anti-cancer
heparins that can be used at optimum anti-tumour levels while
retaining ameliorated anti-thrombotic activity.
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